News Medy-Tox Inc.

Equities

A086900

KR7086900008

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
132,500 ^KRW	+3.43%		-1.63%	-45.02%

Mar. 21	Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 05	South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing	Jan. 05	MT
Medy Tox Establishes Subsidiary Luvantas in California	Jan. 04	MT
Medytox, Inc. Announces the Formation of Luvantas Subsidiary	Jan. 03	CI
Medytox, Inc. Announces Executive Appointments in Luvantas, Inc	Jan. 03	CI
Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
AEON Biopharma, Inc. completed the acquisition of Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	23-07-20	CI
Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
AEON Biopharma, Inc. entered into a definitive business combination agreement to acquire Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	22-12-12	CI
Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on August 17, 2022.	22-09-26	CI
Medy-Tox Inc.'s Equity Buyback announced on August 17, 2022, has closed with 41,771 shares, representing 0.70% for KRW 5,084.38 million.	22-09-21	CI
Medy-Tox Inc.(KOSDAQ:A086900) dropped from FTSE All-World Index	22-09-19	CI
Medy-Tox Inc. announces an Equity Buyback for 41,771 shares.	22-08-17	CI
Medy-Tox Inc. authorizes a Buyback Plan.	22-08-16	CI
Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on June 7, 2022.	22-07-07	CI
Medy-Tox Inc.'s Equity Buyback announced on June 7, 2022, has closed with 39,777 shares, representing 0.66% for KRW 4,574.17 million.	22-07-05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Medy-Tox Inc.

Equities

A086900

KR7086900008

Summary

Filters